SP
BravenNow
Hercules Capital director Randhawa buys $45k in shares
| USA | economy | ✓ Verified - investing.com

Hercules Capital director Randhawa buys $45k in shares

Entity Intersection Graph

No entity connections available yet for this article.

}
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Oil prices dip after 5-day winning streak; set for weekly surge on Iran conflict Trump replaces Homeland Security chief Kristi Noem Wall Street ends lower on escalating Iran conflict, report of AI export curbs Trump says he must be involved in selecting Iran’s next leader (South Africa Philippines Nigeria) Hercules Capital director Randhawa buys $45k in shares By Insider Trading Published 03/06/2026, 12:13 AM Hercules Capital director Randhawa buys $45k in shares 0 HTGC 0.80% Director Paramjeet K. Randhawa of Hercules Capital, Inc. (NASDAQ:HTGC) acquired 3,050 shares of common stock on March 4, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The shares were purchased at a price of $14.78, totaling $45,079. Following the transaction, Randhawa directly owns 19,560 shares of Hercules Capital , Inc. The reported number includes shares acquired through the company’s dividend reinvestment plan. The purchase was signed by Attorney-in-Fact Kiersten Zaza Botelho on March 5, 2026.The insider purchase comes as HTGC stock trades at $15.11 with a P/E ratio of 8.08. According to InvestingPro data, the company offers an attractive dividend yield of 12.44% and has maintained dividend payments for 22 consecutive years. For deeper insights into HTGC’s financial health and dividend sustainability, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities. In other recent news, Hercules Capital, Inc. released preliminary estimates for its fourth-quarter and year-end financials, projecting an increase in net asset value per share to between $12.10 and $12.16 as of December 31, 2025. This represents a rise of $0.05 to $0.11 per share compared to the previous quarter. Meanwhile, Hercules Capital has amended its loan agreement with Savara Inc., providing up to an additional $75 million in funding contingent on FDA approval of Savara’s investigational t...
Read full article at source

Source

investing.com

More from USA

News from Other Countries

🇬🇧 United Kingdom

🇺🇦 Ukraine